US › Healthcare

Liminatus Pharma, Inc. Class A Common Stock (LIMN)

US · Healthcare · Biotechnology

$3.04-5.30%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-1.4M

EPS

$-0.03

Key statistics

Market cap

$4.6M

Forward P/E

0.0

P/B

18.01

Book value

$0.27

EPS (TTM)

$-23.50

52-week high

$141.50

52-week low

$3.25

50-day MA

$4.46

200-day MA

$13.39

Beta

0.75

Shareholding

Insiders

27.18%

Institutions

1.41%

Largest institutional holders

Fund	Stake
XTX Topco Ltd	0.33%
Geode Capital Management, LLC	0.21%
Citadel Advisors Llc	0.08%
Vanguard Capital Management, LLC	0.08%
The Goldman Sachs Group Inc	0.06%
StoneX Group Inc	0.04%
Vanguard Fiduciary Trust Co	0.03%
State Street Corp	0.03%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Liminatus Pharma, Inc. Class A Common Stock — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.